BNP Paribas Financial Markets’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $54K | Buy |
12,256
+602
| +5% | +$3.25K | ﹤0.01% | 4654 |
|
|
2025
Q4 | $74.1K | Buy |
11,654
+1,374
| +13% | +$9.56K | ﹤0.01% | 4507 |
|
|
2025
Q3 | $95.9K | Sell |
10,280
-74,294
| -88% | -$750K | ﹤0.01% | 4320 |
|
|
2025
Q2 | $1.22M | Buy |
84,574
+43,930
| +108% | +$434K | ﹤0.01% | 2792 |
|
|
2025
Q1 | $280K | Sell |
40,644
-15,235
| -27% | -$95.7K | ﹤0.01% | 3525 |
|
|
2024
Q4 | $296K | Sell |
55,879
-17,393
| -24% | -$95.2K | ﹤0.01% | 3645 |
|
|
2024
Q3 | $267K | Buy |
73,272
+69,582
| +1,886% | +$219K | ﹤0.01% | 3138 |
|
|
2024
Q2 | $10.1K | Buy |
3,690
+3,523
| +2,110% | +$11.8K | ﹤0.01% | 3724 |
|
|
2024
Q1 | $581 | Hold |
167
| – | – | ﹤0.01% | 3897 |
|
|
2023
Q4 | $239 | Hold |
167
| – | – | ﹤0.01% | 3922 |
|
|
2023
Q3 | $244 | Hold |
167
| – | – | ﹤0.01% | 3818 |
|
|
2023
Q2 | $262 | Hold |
167
| – | – | ﹤0.01% | 3820 |
|
|
2023
Q1 | $256 | Sell |
167
-90
| -35% | -$160 | ﹤0.01% | 3754 |
|
|
2022
Q4 | $432 | Hold |
257
| – | – | ﹤0.01% | 3873 |
|
|
2022
Q3 | $316 | Sell |
257
-3,601
| -93% | -$5.79K | ﹤0.01% | 4566 |
|
|
2022
Q2 | $6.44K | Sell |
3,858
-2,922
| -43% | -$5.71K | ﹤0.01% | 3799 |
|
|
2022
Q1 | $16.7K | Sell |
6,780
-5,996
| -47% | -$16.4K | ﹤0.01% | 3749 |
|
|
2021
Q4 | $47.8K | Buy |
12,776
+4,005
| +46% | +$21.6K | ﹤0.01% | 3750 |
|
|
2021
Q3 | $55K | Buy |
8,771
+6,920
| +374% | +$57K | ﹤0.01% | 3491 |
|
|
2021
Q2 | $18.3K | Sell |
1,851
-3,502
| -65% | -$30.5K | ﹤0.01% | 3555 |
|
|
2021
Q1 | $50K | Sell |
5,353
-2,594
| -33% | -$20.6K | ﹤0.01% | 3607 |
|
|
2020
Q4 | $38.1K | Sell |
7,947
-1,750
| -18% | -$8.53K | ﹤0.01% | 3672 |
|
|
2020
Q3 | $38.9K | Buy |
9,697
+8,154
| +528% | +$39.3K | ﹤0.01% | 3579 |
|
|
2020
Q2 | $7.08K | Sell |
1,543
-11,180
| -88% | -$50.1K | ﹤0.01% | 3860 |
|
|
2020
Q1 | $41.5K | Buy |
12,723
+7,019
| +123% | +$27K | ﹤0.01% | 3632 |
|
|
2019
Q4 | $24.6K | Sell |
5,704
-618
| -10% | -$2.2K | ﹤0.01% | 3941 |
|
|
2019
Q3 | $24.9K | Buy |
6,322
+1,827
| +41% | +$7.79K | ﹤0.01% | 3853 |
|
|
2019
Q2 | $20.9K | Sell |
4,495
-3,647
| -45% | -$15.6K | ﹤0.01% | 3879 |
|
|
2019
Q1 | $34.1K | Buy |
+8,142
| New | +$29.4K | ﹤0.01% | 3713 |
|
|
2018
Q4 | – | Sell |
-1,258
| Closed | -$5.4K | – | 4446 |
|
|
2018
Q3 | $5.4K | Sell |
1,258
-8
| -0.6% | -$34 | ﹤0.01% | 4024 |
|
|
2018
Q2 | $4.7K | Buy |
1,266
+1,258
| +15,725% | +$4.78K | ﹤0.01% | 4120 |
|
|
2018
Q1 | $34 | Hold |
8
| – | – | ﹤0.01% | 4168 |
|
|
2017
Q4 | $47 | Hold |
8
| – | – | ﹤0.01% | 4160 |
|
|
2017
Q3 | $34 | Hold |
8
| – | – | ﹤0.01% | 4178 |
|
|
2017
Q2 | $31 | Sell |
8
-246
| -97% | -$779 | ﹤0.01% | 4200 |
|
|
2017
Q1 | $683 | Sell |
254
-284
| -53% | -$805 | ﹤0.01% | 3785 |
|
|
2016
Q4 | $1.78K | Sell |
538
-1,408
| -72% | -$3.83K | ﹤0.01% | 3938 |
|
|
2016
Q3 | $5.8K | Buy |
1,946
+814
| +72% | +$2.99K | ﹤0.01% | 3356 |
|
|
2016
Q2 | $4.69K | Buy |
+1,132
| New | +$5.36K | ﹤0.01% | 3296 |
|
Other funds holding NAGE
SW
VCM
TCM
BNP Paribas Financial Markets's NAGE Position: Q1 2026 in Review
BNP Paribas Financial Markets increased its Niagen Bioscience (NAGE) stake by 5.2% in Q1 2026, buying an estimated $3.25K and bringing the position to 12,256 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #4654.
BNP Paribas Financial Markets first reported a position in NAGE in Q2 2016 and has held it in 39 quarters since. The position peaked at $1.22M in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.
- BNP Paribas Financial Markets held 12,256 shares of Niagen Bioscience worth $54K as of Q1 2026.
- BNP Paribas Financial Markets bought 602 Niagen Bioscience shares in Q1 2026, an estimated $3.25K.
- Niagen Bioscience made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4654 holding.
- BNP Paribas Financial Markets first reported a position in Niagen Bioscience in Q2 2016 and has held it in 39 quarters since.
- BNP Paribas Financial Markets's Niagen Bioscience position peaked at $1.22M in Q2 2025.
- 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.